Firstly, the frequency of CDK12 mutation is very low at 1–2% in primary tumors and 5–7% in advanced PCa [12, 14, 15], and cohorts that contain a higher number of patients harboring this mutation and both RNA-seq and genome data are rare. The gene discussed is CDK12; the disease is posterior cortical atrophy.